

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Uni-Bio Science Group Ltd.
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 0690)

VOLUNTARY ANNOUNCEMENT

**STRATEGIC COOPERATION WITH CHINA RESOURCES
ZIZHU FOR GENESOFT®**

The board (“**Board**”) of directors (“**Directors**”) of Uni-Bio Science Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that after the trading hours of The Stock Exchange of Hong Kong Limited on 27 June 2016, Shenzhen Watsin Genetech Limited, a wholly-owned subsidiary of the Company, entered into a strategic alliance agreement (the “**Agreement**”) with China Resources Zizhu Pharmaceutical Co., Ltd. (“**CR Zizhu**”), a subsidiary of China Resources Pharmaceutical Group pursuant to which the Group grant a sole distribution and promotion rights of Genesoft® to CR Zizhu to market and sell Genesoft® in China and introduce Genesoft® into CR Zizhu’s existing domestic hospital network. The Agreement has a term of five years, which can be renewed upon expiry but subject to negotiation.

Under the Agreement, GeneSoft® has immediate access to CR Zizhu’s network for commercializing the drug, a distribution platform with a proven track record and a seasoned sales and marketing team. Currently, GeneSoft® is reimbursed in Jilin and Yunnan provinces as well as Tianjin municipality. The Group believes that through leveraging CR Zizhu’s extensive distribution network and expertise in sales and marketing, distribution of GeneSoft® can be expanded to new regions more quickly, thereby driving further business growth.

* *For identification purpose only*

Genesoft® is an ophthalmic solution containing a derivative of recombinant human epidermal growth factor (rhEGF) which enhances the healing of cornea wounds by promoting corneal epithelium regeneration. The mechanism of action is unique and therefore highly applicable to a wide range of ophthalmology indications, including dry eyes, and trauma after ocular surgery (e.g., LASIK). According to IMS, China's ophthalmology market size has close to tripled in the past 5 years to RMB4 billion in 2014. In the near future, Ophthalmology will continue to be one of the fastest growing indications in China due to aging population and prolonged use of smartphones and computers on a daily basis.

CR Zizhu is a wholly owned subsidiary of China Resource Pharmaceuticals Group, which focuses on development, manufacture and marketing of ophthalmology and reproductive health drugs in China. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge, information and belief, each of CR Zhizhu and its ultimate beneficial owner(s) is a third party independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

By order of the Board
Uni-Bio Science Group Limited
TONG Kit Shing
Chairman

Hong Kong, 27 June 2016

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Tong Kit Shing (Chairman) and Mr. Kingsley Leung; and three independent non-executive Directors, namely, Dr. Carl Aslan Jason Morton Firth, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming.